Bibliography (PubMed) - PDF Free Download

Bibliography (PubMed) Prof. Dr. med. Hans-Joachim Schmoll N Publications total: 420 Impact Factor (cumulative): 1807,55 Citation-Factor (Hirsch) : 64 No. of Publications per year (1997-2016) No. of Citations per year (1997-2016)

Bibliography according to PubMed with Impact Factor Prof.Dr.med.habil. Hans-Joachim Schmoll 1. Schwoon DR, Schmoll HJ: (1979) Motivation to participate in cancer screening programmes. SOC SCI MED, 13: 283-6. IF: 2,742, anteiliger IF: 1,371 1979 Summe Bewertung = 1,371 Summe IF = 2,742 2. Schmoll HJ, Niederle N, Achterrath W: (1981) [Etoposide VP 16--213)--a podophyllotoxinderivative with high antitumor activity (author's transl)]. KLIN WOCHENSCHR, 59: 1177-88. 7031350 IF: 0,809, anteiliger IF: 0,2697 1981 Summe Bewertung = 0,2697 Summe IF = 0,809 3. Freise J, Mueller WH, Magerstedt P, Schmoll HJ (1982) Pharmacokinetics of liposome encapsulated cisplatin in rats. ARCH INT PHARMACODYN THER 258: 180-92 IF: 2,103, anteiliger IF: 0,701 4. Schmoll H.(1982) Review of etoposide single-agent activity. Cancer Treat Rev. Jun;9 Suppl:21-30. IF: 4,7 anteiliger IF: 4,7 5. Schindler E, Waegner W, Schmoll H, Zockler H.. [Role of lymphadenectomy in stages I and II of non-seminoma tumors. Report of their modern chemotherapy (author's transl)]. J Urol (Paris). 1982;88(5):295-9 IF: 1,91 anteiliger IF: 0,81833 1982 Summe Bewertung = 5,71933 Summe IF = 8,713 6. Weiss J, von Roemeling R, Peters HD, Schmoll HJ, Diehl V: (1983) [Chemotherapy in pretreated Hodgkin's disease with lomustine, bleomycin, vinblastine and dexamethasone]. Dtsch Med Wochenschr, 108: 1428-32. 6192987 IF: 0,528, anteiliger IF: 0,0587

7. Hacke M, Schmoll HJ, Alt JM, Baumann K, Stolte H (1983) Nephrotoxicity of cisdiamminedichloroplatinum with or without ifosfamide in cancer-treatment. Clin. Physiol. Biochem., 1:17-26. IF: 1,213, anteiliger IF: 0,20217 1983 Summe Bewertung = 0,26087 Summe IF = 1,741 8. Klose E, Ritter EP, Massopust D, Endert G, Schumann E, Hasse P, Schmoll H, Beyer HK. [Exposure technics for computed scintigrams]. Rofo. 1984 Jul;141(1):97-9. IF: 1,005 anteiliger IF:0,05584 1984 Summe Bewertung = 0,05584 Summe IF = 1,005 9. Gabius HJ, Engelhardt R, Casper J, Reile D, Schumacher S, Schmoll HJ, Graupner G, Cramer F: (1985) Cell surface lectins of transplantable human teratocarcinoma cells: purification of a new mannan-specific endogenous lectin. TUMOR BIOL, 6: 145-56. 4048775 IF: 2,143, anteiliger IF: 0,1906 1985 Summe Bewertung = 0,1906 Summe IF = 2,143 10. Gabius HJ, Engelhardt R, Casper J, Schmoll HJ, Nagel GA, Cramer F: (1986) Comparison of endogenous lectins in human embryonic carcinoma and yolk sac carcinoma. TUMOR BIOL, 6: 471-82. 3010437 IF: 2,143, anteiliger IF: 0,178584 11. Peest D, Schmoll HJ, Schedel I, Deicher H, Boll J, Essers U, Gamm H, Gluck S, Gorg K, Gramatzki M, et A: (1986) Current results of a multicenter trial in multiple myeloma. Onkologie, 9: 168-9. 3528964 IF: 0,868, anteiliger IF: 0,03617 1986 Summe Bewertung = 3,011 Summe IF = 0,214754 12. Berdel WE, Berger MR, Falk H, Harstrick A, Danhauser S, Schick HD, Schmoll HJ, Schmahl D, Vogler WR, Rastetter J: (1987) Lack of therapeutic activity of the lipoidal amine CP-46,665 in rodent tumors and human non-seminomatous germ cell tumors growing in nude mice. CANCER LETT, 38: 191-7. 2825966 IF: 4,238, anteiliger IF: 0,17658

13. Casper J, Schmoll HJ, Schnaidt U, Fonatsch C: (1987) Cell lines of human germinal cancer. INT J ANDROL, 10: 105-13. 3034787 IF: 3,519, anteiliger IF: 0,5865 14. Creutzig A, Polking W, Schmoll HJ, Fabel H, Alexander K: (1987) [Raynaud syndrome and changes in lung function as sequelae of cytostatic therapy of testicular tumors]. Med Klin Intensivmed Notfmed, 82: 131-4. 2436030 IF: 0,343, anteiliger IF: 0,0382 15. Gabius HJ, Bokemeyer C, Hellmann T, Schmoll HJ: (1987) Targeting of neoglycoprotein-drug conjugates to cultured human embryonal carcinoma cells. J CANCER RES CLIN, 113: 126-30. 3031079 IF: 2,558 anteiliger IF: 0,8527 16. Harstrick A, Casper J, Schmoll HJ: (1987) Comparative antitumour activity of cisplatin and two new cisplatin-analogues JM8 and JM9 in human testicular carcinoma xenografts. INT J ANDROL, 10: 139-45. 3034790 IF: 3,591, anteiliger IF: 1,197 17. Schmoll HJ, Schubert I, Arnold H, Dolken G, Hecht T, Bergmann L, Illiger J, Fink U, Preiss J, Pfreundschuh M, et A: (1987) Disseminated testicular cancer with bulky disease: results of a phase-ii study with cisplatin ultra high dose/vp-16/bleomycin. INT J ANDROL, 10: 311-7. 2438224 IF: 3,591, anteiliger IF: 1,197 18. von Wussow P, Freund M, Block B, Diedrich H, Schmoll H, Poliwoda H, Deicher H. [Low-dose alpha-interferon treatment of hairy cell leukemia]. Klin Wochenschr. 1987 Jul 15;65(14):681-4. IF: 0,1 anteiliger IF: 0,00666 1987 Summe Bewertung = 4,05464 Summe IF = 17,94 19. Calavrezos A, Koschel G, Husselmann H, Taylessani A, Heilmann HP, Fabel H, Schmoll HJ, Dietrich H, Hain E: (1988) Malignant mesothelioma of the pleura. A prospective therapeutic study of 132 patients from 1981-1985. KLIN WOCHENSCHR, 66: 607-13. 3210656 IF: 0,809 anteiliger IF: 0,03852 20. Peest D, Schmoll HJ, Schedel I, Gluck S, Schumacher K, Deicher H: (1988) VBAMDex chemotherapy in advanced multiple myeloma. EUR J HAEMATOL, 40: 245-9. 3356240 IF: 2,004, anteiliger IF: 0,167

21. Verbeek W, Bokemeyer C, Falk H, Schmoll HJ: (1988) Growth requirements, growth factor responsiveness, and growth factor secretion of three human embryonal carcinoma cell lines. J CANCER RES CLIN, 114: 553-8. 3204101 IF: 2,558 anteiliger IF: 0,8527 22. Wilke H, Achterrath W, Schmoll HJ, Gunzer U, Preusser P, Lenaz L: (1988) Etoposide and split-dose cisplatin in small-cell lung cancer. AM J CLIN ONCOL-CANC, 11: 572-8. 2845770 IF: 2,002 anteiliger IF: 0,16684 23. Wilke H, Schmoll HJ, Preusser P, Fink U, Stahl M, Schober C, Link H, Freund M, Hanauske A, Meyer HJ, et A: (1988) Folinic acid (CF)/5-fluorouracil (FUra) combinations in advanced gastrointestinal carcinomas. ADV EXP MED BIOL, 244: 233-43. 3073658 IF: 1,093 anteiliger IF: 0,04554 24. Wilke H, Schmoll HJ, Schober C, Stahl M, Preusser P, Freund M, Poliwoda H: (1988) Folinic acid (FA) plus 5-fluorouracil (FU) in progressive advanced colorectal cancer. BIOMED PHARMACOTHER, 42: 373-80. 3064821 IF: 2 anteiliger IF: 0,14 25. Peest D, Deicher H, Coldewey R, Schmoll HJ, Schedel I (1988) Induction and maintenance-therapy in multiple myeloma: A multicenter trial of MP vs. VCMP. EUR J CANCER CLIN ONCOL, 24:1061-7 IF: 5,536 anteiliger IF: 0,6152 1988 Summe Bewertung = 2,0258 Summe IF = 16,002 26. Arnemann J, Gradl G, Casper J, Schmoll HJ, Schmidtke J, Fonatsch C: (1989) Characterization of rearranged Y chromosomes in human testicular tumor cell lines. CANCER GENET CYTOGEN, 37: 141-51. 2539248 IF: 1,389, anteiliger IF: 0,11575 27. Bokemeyer B, Grote R, Schmoll E, Freise J, Schmoll HJ, Galanski M, Schuler A, Schmidt FW: (1989) [Chemoembolization of hepatocellular carcinoma with lipiodol, epirubicin and cisplatin]. Dtsch Med Wochenschr, 114: 128-32. 2536606 IF: 0,528 anteiliger IF: 0,0294 28. Harstrick A, Casper J, Guba R, Wilke H, Poliwoda H, Schmoll HJ: (1989) Comparison of the antitumor activity of cisplatin, carboplatin, and iproplatin against established human testicular cancer cell lines in vivo and in vitro. CANCER-AM CANCER SOC, 63: 1079-83. 2645036 IF: 4,771 anteiliger IF: 1,5904 29. Schmoll HJ: (1989) The role of ifosfamide in testicular cancer. SEMIN ONCOL, 16(1 Suppl 3): 82-95. 2649987

IF: 3,5 anteiliger IF: 3,5 30. Winkler K, Torggler S, Beron G, Bode U, Gerein V, Jurgens H, Kusnierz-Glaz C, Kotz R, Salzer-Kuntschik M, Schmoll HJ, et A: (1989) [Results of treatment in primary disseminated osteosarcoma. Analysis of the follow-up of patients in the cooperative osteosarcoma studies COSS-80 and COSS-82]. Onkologie, 12: 92-6. 2660050 IF: 0,173 anteiliger IF: 0,0577 26. Meyer HJ, Jahne J, Pichlmayr R, Wilke H, Schmoll HJ, Poliwoda H (1989) Interdisciplinary therapy concepts in gastrointestinal tumors: Stomach. Z Gastroenterol Verh, 24:60-5. IF: 0.067 anteiliger IF: 0,00558 27. Schmoll HJ, (1989) The role of ondansetron in the treatment of emesis induced by non-cisplatin-containing chemotherapy regimes. EUR J CANCER CLON ONCOL, 25:35-9. IF: 5,536 anteiliger IF: 5,536 1989 Summe Bewertung = 10,83483 Summe IF = 15,964 28. Harstrick A, Casper J, Kohne-Wompner H, Wilke H, Schmoll HJ, Poliwoda H: (1990) Comparative activity of four anthracyclines against heterotransplanted germ cell tumor lines. INVEST NEW DRUG, 8: S19-24. 1696245 IF: 3,357 anteiliger IF: 0,27975 29. Harstrick A, Schmoll HJ, Casper J, Wilke H, Poliwoda H: (1990) Activity of cytostatic drugs in two heterotransplanted human testicular cancer cell lines with different sensitivity to standard agents. EUR J CANCER, 26: 898-901. 2145935 IF: 5,536 anteiliger IF: 0,6152 30. Harstrick A, Schmoll HJ, Wilke H, Schober C, Stahl M, Wompner CK, Bokemeyer C, Dolken G, Burk K, Poliwoda H: (1990) High dose epirubicin in refractory or relapsed non-seminomatous testicular cancer: a phase II study. ANN ONCOL, 1: 375-6. 2261377 IF: 3, anteiliger IF: 0,125 31. Jackle-Meyer I, Gwinner W, Baum M, Soose M, Petzoldt R, Schmoll HJ, Stolte H: (1990) Significance of Tamm-Horsfall protein excretion in diabetes mellitus and cisplatin nephrotoxicity. CONTRIB NEPHROL, 83: 124-9. 2100702 IF: 1,487 anteiliger IF: 0,09914 32. Preusser P, Wilke H, Achterrath W, Lenaz L, Stahl M, Casper J, Meyer HJ, Meyer J, Blum M, Schmoll HJ: (1990) Phase II study of carboplatin in untreated inoperable advanced stomach cancer. EUR J CANCER, 26: 1108-9. 2148891

IF: 5,536 anteiliger IF: 1,8454 33. Schmoll HJ: (1990) Progress in treatment of testicular cancer. J CANCER RES CLIN, 116: 112-5. 2312601 IF: 2,558 anteiliger IF: 2,558 34. Schmoll HJ, Harstrick A, Kohne-Wompner CH, Schober C, Wilke H, Poliwoda H: (1990) Modulation of cytotoxic drug activity by dipyridamole. Cancer Treat Rev, 17: 57-65. 2092872 IF: 6,054 anteiliger IF: 2,018 35. Tesch H, Furbass R, Casper J, Lyons J, Bartram CR, Schmoll HJ, Bronson DL: (1990) Cellular oncogenes in human teratocarcinoma cell lines. INT J ANDROL, 13: 377-88. 2283183 IF: 3,591 anteiliger IF: 0,2394 1990 Summe Bewertung = 7,65489 Summe IF = 28,119 36. Harstrick A, Schmoll HJ, Bokemeyer C, Metzner B, Illiger HJ, Berdel W, Ostermann H, Manegold C, Rath U, Siegert W, et A: (1991) Cisplatin/etoposide/ifosfamide stepwise dose escalation with concomitant granulocyte/macrophage-colony-stimulating factor for patients with faradvanced testicular carcinoma. J CANCER RES CLIN, 117: S198-202. 1665492 IF: 2,558 anteiliger IF: 0,10658 37. Harstrick A, Schmoll HJ, Kohne-Wompner CH, Bergmann L, Lammers U, Hohnloser J, Dolken G, Reichhardt P, Siegert W, Natt F, et A: (1991) Cisplatin, etoposide, ifosfamide, vincristine and bleomycin combination chemotherapy for far advanced testicular carcinoma. ANN ONCOL, 2: 197-202. 1710481 IF: 4,425 anteiliger IF: 0,18438 38. Harstrick A, Schmoll HJ, Wilke H, Kohne-Wompner CH, Stahl M, Schober C, Casper J, Bruderek L, Schmoll E, Bokemeyer C, et A: (1991) Cisplatin, etoposide, and ifosfamide salvage therapy for refractory or relapsing germ cell carcinoma. J CLIN ONCOL, 9: 1549-55. 1651992 IF: 1,41, anteiliger IF: 0,05875 39. Schmoll E, Wilke H, Thole R, Preusser P, Wildfang I, Schmoll HJ: (1991) Megestrol acetate in cancer cachexia. SEMIN ONCOL, 18(1 Suppl 2): 32-4. 1992534 IF: 3,5 anteiliger IF: 1,17 40. Schmoll HJ: (1991) How should we treat disseminated seminoma? ANN ONCOL, 2: 623-4. 1742217 IF: 1,917 anteiliger IF: 1,917

41. Schmoll HJ: (1991) Introduction: the clinical challenge. EUR J CANCER, 27: S1-2. 1831627 IF: 5,536 anteiliger IF: 5,536 42. Schuppert F, Scheumann GFW, Schöber C, Overbeck J, Schürmeyer T, Schmoll HJ, Dralle H, von zur Mühlen A: (1991) Therapie eines malignen sympathischen Paraganglioms des Zuckerkandlschen Organs - ein Fallbericht. KLIN WOCHENSCHR, 69: 937-942 IF: 0,809 anteiliger IF: 0,05394 43. Wilke H, Preusser P, Stahl M, Harstrick A, Meyer HJ, Achterrath W, Schmoll HJ, Seeber S: (1991) Etoposide, folinic acid, and 5-fluorouracil in carboplatinpretreated patients with advanced gastric cancer. CANCER CHEMOTH PHARM, 29: 83-4. 1742854 IF: 2,833 anteiliger IF: 0,15739 44. Wilke H, Preusser P, Fink U, Meyer HJ, Schmoll HJ, Stahl M, Seeber S, (1991) Modern therapeutic strategies in stomach cancer. Z GASTROENTEROL VERH, 26:217-8 IF:0,896, anteiliger IF: 0,05974 1991 Summe Bewertung = 9,24378 Summe IF = 23,884 45. Bokemeyer C, Freund M, Schmoll HJ, Rieder H, Fonatsch C: (1992) Secondary lymphoblastic leukemia following treatment of a malignant germ cell tumour. ANN ONCOL, 3: 772. 1280461 IF: 6,425 anteiliger IF: 0,7139 46. Bokemeyer C, Harstrick A, Schmoll HJ, Kohne-Wompner CH, Schoffski P, Poliwoda H: (1992) Epirubicin/dacarbazine rapidly alternated with ifosfamide in the treatment of metastatic soft tissue sarcomas. ANN ONCOL, 3: 487-8. 1498067 IF: 6,425 anteiliger IF: 0,3542 47. Bokemeyer C, Harstrick A, Schoffski P, Schmoll HJ, Poliwoda H: (1992) [Germ-cell tumors of the testis. The epidemiological and etiological aspects]. Dtsch Med Wochenschr, 117: 1532-7. 1327710 IF: 0,528 anteiliger IF: 0,0587 48. Galanski M, Schmoll E, Reichelt S, Bohmer G, Prokop M, Schaefer C, Schuler A, Ringe B, Schmidt FW, Schmoll HJ: (1992) [Chemoembolization of hepatocellular carcinoma in cases of isolated liver involvement]. RADIOLOGE, 32: 49-55. 1314400 IF: 0,611 anteiliger IF: 0,2037 49. Harstrick A, Bokemeyer C, Preusser P, Kohne-Wompner CH, Meyer HJ, Stahl M, Knipp H, Schmoll HJ, Wilke H: (1992) Phase II study of single-agent

etoposide in patients with metastatic squamous-cell carcinoma of the esophagus. CANCER CHEMOTH PHARM, 29: 321-2. 1537080 IF: 3,5 anteiliger IF: 0,16666 50. Kohne-Wompner CH, Schmoll HJ, Harstrick A, Rustum YM: (1992) Chemotherapeutic strategies in metastatic colorectal cancer: an overview of current clinical trials. SEMIN ONCOL, 19(2 Suppl 3): 105-25. 1373004 IF: 3,5 anteiliger IF: 0,584 51. Schmoll HJ, Bokemeyer C, Harstrick A, Illiger HJ, Metzner B, Ruther U, Osternamm A, Preiss J, Wilke H, Hohnloser J, et A: (1992) Dose escalation of cisplatin (P), etoposide (E), and ifosfamide (I) with GM-CSF for advanced germ cell tumors. PATHOL BIOL, 39: 961. 1538953 IF: 1,528 anteiliger IF: 0,5094 52. Schmoll HJ, Hiddemann W, Rustum Y, Kohne-Wompner CH: (1992) The emerging role for biomodulation of antineoplastic agents. SEMIN ONCOL, 19(2 Suppl 3): 1-3. 1557636 IF: 2,194 anteiliger IF: 0,7314 53. Schmoll HJ, Kohne-Wompner CH, Hiddemann W, Knipp H, Wilke H, Bodenstein H, Schoffski P, Bokemeyer C, Lohrmann HP, Preiss J, et A: (1992) Interferon alpha-2b, 5-fluorouracil, and folinic acid combination therapy in advanced colorectal cancer: preliminary results of a phase I/II trial. SEMIN ONCOL, 19(2 Suppl 3): 191-6. 1557646 IF: 2,194 anteiliger IF: 0.7314 54. Schober C, Bokemeyer C, Stahl M, Wilke HJ, Schmoll HJ, Poliwoda H: (1992) The role of schedule dependency of 5-fluorouracil/leucovorin combinations in advanced colorectal cancer. SEMIN ONCOL, 19(2 Suppl 3): 131-5. 1557638 IF: 2,194 anteiliger IF: 0,18284 55. Schober C, Kohne-Wompner CH, Schmoll HJ, Stahl M, Wilke HJ, Poliwoda H: (1992) A 3-day schedule of 5-fluorouracil and folinic acid in metastatic progressive colorectal cancer and its impact in terms of palliation. SEMIN ONCOL, 19(2 Suppl 3): 136-40. 1557639 IF: 2,194 anteiliger IF: 0,18284 56. Schober C, Schmoll E, Schmoll HJ, Poliwoda H, Schuppert F, Stahl M, Bokemeyer C, Wilke H, Weiss J: (1992) Antitumour effect and symptomatic control with interferon alpha 2b in patients with endocrine active tumours. EUR J CANCER, 28: 1664-6. 1382494 IF: 2,191 anteiliger IF: 0,1044 57. Stahl M, Wilke HJ, Seeber S, Schmoll HJ: (1992) Cytokines and cytotoxic agents in renal cell carcinoma: a review. SEMIN ONCOL, 19(2 Suppl 4): 70-9. 1553577 IF: 2,194 anteiliger IF: 0,7314 58. Stahl M, Wilke H, Schmoll HJ, Schober C, Diedrich H, Casper J, Freund M, Poliwoda H: (1992) A phase II study of high dose tamoxifen in progressive, metastatic renal cell carcinoma. ANN ONCOL, 3: 167-8. 1606089

IF: 1,917 anteiliger IF: 0,1065 59. Wilke H, Stahl M, Schmoll HJ, Preusser P, Fink U, Meyer HJ, Achterrath W, Knipp H, Kohne-Wompner CH, Harstrick A, et A: (1992) Biochemical modulation of 5-fluorouracil by folinic acid or alpha-interferon with and without other cytostatic drugs in gastric, esophageal, and pancreatic cancer. SEMIN ONCOL, 19(2 Suppl 3): 215-9. 1557651 IF: 2,194 anteiliger IF: 0,09142 1992 Summe Bewertung = 5,37004 Summe IF = 34,095 60. Bokemeyer C, Kuczyk M, Schoffski P, Schmoll HJ: (1993) Familial occurrence of Leydig cell tumors: a report of a case in a father and his adult son. J UROLOGY, 150(5 Pt 1): 1509-10. 8411441 IF: 0,105 anteiliger IF: 0,035 61. Bokemeyer C, Luer M, Schmoll HJ, Freund M, Poliwoda H: (1993) Secondary cancer following Hodgkin's disease. ANN ONCOL, 4: 520-1. 8353097 IF: 1,917 anteiliger IF: 0,213 62. Bokemeyer C, Schmoll HJ: (1993) Secondary neoplasms following treatment of malignant germ cell tumors. J CLIN ONCOL, 11: 1703-9. 8394879 IF: 0,561 anteiliger IF: 0,2805 63. Bokemeyer C, Schmoll HJ: (1993) Treatment of advanced germ cell tumours by dose intensified chemotherapy with haematopoietic growth factors or peripheral blood stem cells (PBSC). Eur Urol, 23: 223-9; discussion 230. 8097467 IF: 8,493 anteiliger IF: 4,265 64. Bokemeyer C, Schmoll HJ: (1993) Treatment strategies in metastatic testicular cancer. Eur Urol, 23: 50-2. 8390363 IF: 1,959 anteiliger IF: 0,9795 65. Bokemeyer C, Schmoll HJ, Harstrick A: (1993) Side-effects of GM-CSF treatment in advanced testicular cancer. EUR J CANCER, 29: 924. 8484987 IF: 1,959 anteiliger IF: 0,653 66. Bokemeyer C, Schmoll HJ, Harstrick A, Illiger HJ, Metzner B, Rath U, Hohnloser J, Clemm C, Berdel W, Siegert W, et A: (1993) A phase I/II study of a stepwise dose-escalated regimen of cisplatin, etoposide and ifosfamide plus granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with advanced germ cell tumours. EUR J CANCER, 29: 2225-31. 8110490 IF: 1,41, anteiliger IF: 0,05875 67. Bokemeyer C, Schmoll HJ, Metzner B, Beyer J, Illiger HJ, Kneba M, Ostermann H, Kynast B, Rath U, Poliwoda H: (1993) Comparison of 5 vs 10 micrograms/kg per day of GM-CSF following dose-intensified chemotherapy with cisplatin, etoposide, and ifosfamide in patients with advanced testicular

cancer. ANN HEMATOL, 67: 75-9. 8347733 IF: 1,959, anteiliger IF: 0,08163 68. Bokemeyer C, Schmoll HJ, Schoffski P, Harstrick A, Bading M, Poliwoda H: (1993) Bilateral testicular tumours: prevalence and clinical implications. EUR J CANCER, 29: 874-6. 8387319 IF: 1,959 anteiliger IF: 0,16325 69. Erlichman C, Fine S, Kerr I, Hoffman W, Gorg C, Schmoll HJ, Preusser P, Senn HJ, Gustavsson B: (1993) Experience with 5FU + L-leucovorin. ADV EXP MED BIOL, 339: 77-9; discussion 97-8. 8178731 IF: 0,561 anteiliger IF: 0,02671 70. Grigor KM, Schmoll HJ: (1993) How should we identify high risk testicular tumour patients? Round table discussion. Eur Urol, 23: 207-12. 8386651 IF: 1,307 anteiliger IF: 0,6535 71. Grigor KM, Schmoll HJ: (1993) Should high dose chemotherapy with, or without, autologous bone marrow transplant be included in the primary treatment of testicular cancer? Round table discussion. Eur Urol, 23: 240-4. 8386655 IF: 0,561 anteiliger IF: 0,2805 72. Grundner-Culemann E, Bokemeyer C, Neubauer V, Shalitin C, Schmoll HJ, Poliwoda H, Benter T: (1993) Analysis of a non-ras 21-kDa protein in patients with metastatic testicular germ-cell tumors. J CANCER RES CLIN, 119: 685-8. 8394368 IF: 1,041 anteiliger IF: 0,0694 73. Harstrick A, Bokemeyer C, Scharnofkse M, Hapke G, Reile D, Schmoll HJ: (1993) Preclinical activity of a new platinum analogue, lobaplatin, in cisplatinsensitive and -resistant human testicular, ovarian, and gastric carcinoma cell lines. CANCER CHEMOTH PHARM, 33: 43-7. 8269588 IF: 1,041 anteiliger IF: 0,347 74. Harstrick A, Bokemeyer C, Schmoll HJ, Kohne-Wompner CH, Knipp H, Schoffski P, Anagnou J, Wipperman B, Neumann S, Poliwoda H: (1993) A pilot study of rapidly alternating epirubicin/dacarbazine and ifosfamide as firstline therapy for metastatic soft-tissue sarcoma in adults. CANCER CHEMOTH PHARM, 31: S217-21. 8453702 IF: 2,833 anteiliger IF: 0,11804 75. Harstrick A, Schmoll HJ, Sass G, Poliwoda H, Rustum Y: (1993) Titanocendichloride activity in cisplatin and doxorubicin-resistant human ovarian carcinoma cell lines. EUR J CANCER, 29: 1000-2. 8499130 IF: 1,959 anteiliger IF: 0,2177 76. Kohne-Wompner CH, Schmoll HJ: (1993) 5-Fluorouracil modulation in colorectal carcinoma experience of German investigators. ADV EXP MED BIOL, 339: 99-107. 8178734 IF: 1, anteiliger IF: 0,5

77. Kynast B, Binder L, Marx D, Zoll B, Schmoll HJ, Oellerich M, Schauer A: (1993) Determination of a fragment of the c-erbb-2 translational product p185 in serum of breast cancer patients. J CANCER RES CLIN, 119: 249-52. 8095050 IF: 1,307 anteiliger IF: 0,08714 78. Schmoll HJ, Harstrick A, Bokemeyer C, Dieckmann KP, Clemm C, Berdel WE, Souchon R, Schober C, Wilke H, Poliwoda H: (1993) Single-agent carboplatinum for advanced seminoma. A phase II study. CANCER-AM CANCER SOC, 72: 237-43. 8508413 IF: 2,429 anteiliger IF: 0,8096 79. Schmoll HJ, Seeber S: (1993) [Current developments in chemotherapy of advanced testicular tumors]. Urologe A, 32: 207-16. 8511834 IF: 0,36 anteiliger IF: 0,18 80. Schmoll HJ (1993) Management of eary stages of testicular carcinoma: the current status. RECENT RESULTS CANCER RES, 126:237-55 IF: 0,952, anteiliger IF: 0,952 81. Bokemeyer C, Schmoll H, Harstrick A, Kohnewompner H, Poliwoda H. Treatment of adult osteosarcoma - single-center results in 47 patients. Int J Oncol. 1993 Nov;3(5):927-32. IF: 1,181 anteiliger IF: 0,13122 82. Bokemeyer C 1, Schmoll H, Casper J, Kuczyk M, Poliwoda H. No growthstimulation of heterotransplanted human testicular cancer cell-lines by recombinant human granulocyte-macrophage colony-stimulating factor (gmcsf). Int J Oncol. 1993 Jul;3(1):77-80. IF: 1,181 anteiliger IF: 0,13122 83. Bokemeyer C 1, Frank B, Schoffski P, Poliwoda H, Schmoll H. Phantom sensations after orchiectomy for testicular cancer. Int J Oncol. 1993 Apr;2(4):633-6. IF: 1,181 anteiliger IF: 0,39366 84. Bokemeyer C 1, Harstrick A, Gonnermann O, Schober C, Kuczyk M, Poliwoda H, Schmoll H. Metastatic leydig-cell tumors of the testis - report of 4 cases and review of the literature. Int J Oncol. 1993 Feb;2(2):241-4.

IF: 1,181 anteiliger IF : 0,39366 1993 Summe Bewertung = 12,02088 Summe IF = 40,397 85. Beyer J, Bokemeyer C, Schmoll HJ, Siegert W: (1994) Treatment intensification in disseminated germ-cell tumors. World J Urol, 12: 207-13. 7820143 IF: 0,561, anteiliger IF: 0,09352 86. Bokemeyer C, Dunn T, Harstrick A, Lerch T, Poliwoda H, Schmoll HJ: (1994) Modulation of cytostatic drugs by nifedipine in two heterotransplanted human testicular-cancer cell lines differing in their sensitivity to standard agents. Int J Cancer, 56: 452-6. 7906255 IF: 3,276, anteiliger IF: 1,09189 87. Bokemeyer C, Harstrick A, Ruther U, Metzner B, Illiger HJ, Clemm C, Siegert W, Link H, Ostermann H, Schmoll HJ: (1994) The role of granulocytemacrophage colony-stimulating factor in the treatment of germ cell tumors. German Testicular Cancer Study Group. SEMIN ONCOL, 21(6 Suppl 16): 57-63. 7801148 IF: 2,628, anteiliger IF: 0,87591 88. Bokemeyer C, Harstrick A, Schmoll HJ: (1994) The use of carboplatin in malignant germ cell tumours. EUR J CANCER, 30: 721-2. 8080698 IF: 0,789, anteiliger IF: 0,26297 89. Bokemeyer C, Schmoll HJ, Ludwig E, Harstrick A, Dunn T, Casper J: (1994) The anti-tumour activity of ifosfamide on heterotransplanted testicular cancer cell lines remains unaltered by the uroprotector mesna. BRIT J CANCER, 69: 863-7. 8180015 IF: 3,188, anteiliger IF: 0,26572 90. Bokemeyer C, Schmoll HJ, Natt F, Knoche M, Beyer J, Souchon R: (1994) Preliminary results of a phase I/II trial of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer. J CANCER RES CLIN, 120: 754-7. 7798304 IF: 1,654, anteiliger IF: 0,13786 91. Bokemeyer C, Schmoll HJ, Poliwoda H: (1994) [Secondary leukemias after etoposide chemotherapy]. Dtsch Med Wochenschr, 119: 707-13. 8187625 IF: 0,605, anteiliger IF: 0,20171 92. Bokemeyer C, Schmoll HJ, van Rhee J, Kuczyk M, Schuppert F, Poliwoda H: (1994) Long-term gonadal toxicity after therapy for Hodgkin's and non- Hodgkin's lymphoma. ANN HEMATOL, 68: 105-10. 8167175 IF: 1,496, anteiliger IF: 0,12469

93. Derigs HG, Huber C, Schmoll HJ: (1994) [Stage-oriented therapy in nonseminomatous testicular tumors]. Dtsch Med Wochenschr, 119: 156-64. 8313845 IF: 0,605, anteiliger IF: 0,20165 94. Hill BT, Shellard SA, Fichtinger-Schepman AM, Schmoll HJ, Harstrick A: (1994) Differential formation and enhanced removal of specific cisplatin-dna adducts in two cisplatin-selected resistant human testicular teratoma sublines. ANTI-CANCER DRUG, 5: 321-8. 7919457 IF: 1,258, anteiliger IF: 0,13981 95. Kohne-Wompner CH, Schoffski P, Schmoll HJ: (1994) Adjuvant therapy for colon adenocarcinoma: current status of clinical investigation. ANN ONCOL, 5: 97-104. 8204538 IF: 1,914, anteiliger IF: 0,63794 96. Link H, Herrmann F, Welte K, Aulitzky WE, Ganser A, Kern WV, Meyer P, Schrappe M, Schmoll HJ, Werdan K, et A: (1994) [Rational therapy with G- CSF and GM-CSF]. Med Klin Intensivmed Notfmed, 89: 429-41. 7526144 IF: 0,5 anteiliger IF: 0,02084 97. Schmoll HJ: (1994) [Adjuvant chemotherapy in rectal cancer]. CHIRURG, 65: 576-84. 7924595 IF: 0,657, anteiliger IF: 0,657 98. Schmoll HJ: (1994) Colorectal carcinoma: current problems and future perspectives. ANN ONCOL, 5: 115-21. 8204526 IF: 1,914, anteiliger IF: 1,914 99. Siegert W, Beyer J, Strohscheer I, Baurmann H, Oettle H, Zingsem J, Zimmermann R, Bokemeyer C, Schmoll HJ, Huhn D: (1994) High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: a phase I/II study. The German Testicular Cancer Cooperative Study Group. J CLIN ONCOL, 12: 1223-31. 7911158 IF: 7,507, anteiliger IF: 0,31285 100. Casper J 1, Casper S, Kohnewompner C, Bokemeyer C, Hecker H, Schmoll H. 5-ht3 antagonist ondansetron for the treatment of chemotherapyinduced nausea and vomiting in an outpatient population. Int J Oncol. 1994 Jun;4(6):1283-9. IF:1,181 anteiliger IF: 0,3937 1994 Summe Bewertung = 7,33206 Summe IF = 29,733

101. Bajorin DF, Nichols CR, Schmoll HJ, Kantoff PW, Bokemeyer C, Demetri GD, Einhorn LH, Bosl GJ: (1995) Recombinant human granulocytemacrophage colony-stimulating factor as an adjunct to conventional-dose ifosfamide-based chemotherapy for patients with advanced or relapsed germ cell tumors: a randomized trial. J CLIN ONCOL, 13: 79-86. 7799046 IF: 6,922, anteiliger IF: 0,38463 102. Berger CC, Bokemeyer C, Schneider M, Kuczyk MA, Schmoll HJ: (1995) Secondary Raynaud's phenomenon and other late vascular complications following chemotherapy for testicular cancer. EUR J CANCER, 31: 2229-38. 8652248 IF: 2,095, anteiliger IF: 0,69826 103. Bokemeyer C, Kynast B, Harstrick A, Laage E, Schmoll E, von Wussow P, Schmoll HJ: (1995) No synergistic activity of epirubicin and interferon-alpha 2b in the treatment of hepatocellular carcinoma. CANCER CHEMOTH PHARM, 35: 334-8. 7828277 IF: 1,598, anteiliger IF: 0,53261 104. Bokemeyer C, Ludwig E, Reile D, Harstrick A, Poliwoda H, Schmoll HJ: (1995) Antitumour activity and toxicity of continuous infusion versus bolus administration of bleomycin in two heterotransplanted human testicular cancer cell lines. Oncol Rep, 2: 161-165 IF: 0,421, anteiliger IF: 0,14032 105. Bokemeyer C, Schmoll HJ: (1995) Treatment of testicular cancer and the development of secondary malignancies. J CLIN ONCOL, 13: 283-92. 7799032 IF: 6,922, anteiliger IF: 3,461 106. Bokemeyer C, Schmoll HJ: (1995) Sekundärneoplasien nach der Therapie maligner Keimzelltumoren des Hodens. Strahlenther Onkol, 6: 356-357 IF: 2,5 anteiliger IF: 1,25 107. Bokemeyer C, Schmoll HJ, Kuczyk MA, Beyer J, Siegert W: (1995) Risk of secondary leukemia following high cumulative doses of etoposide during chemotherapy for testicular cancer. JNCI-J NATL CANCER I, 87: 58-60. 7666466 IF: 10,165, anteiliger IF: 1,12967 108. Köhne CH, Hiddemann W, Schüller J, Weiss J, Lorhmann HP, Schmitz- Hübner U, Bodenstein H, Schöber C, Wilke H, Grem J, Schmoll HJ: (1995) Failure of orally administered Dipyridamole to enhance the antineoplastic activity for Fluorouracil in combination with Leucovorin in patients with advanced colorectal cancer: a prospective randomized trial. J CLIN ONCOL, 13: 1201-1208 IF: 6,922, anteiliger IF: 2,3071 109. Köhne CH, Schmoll HJ: (1995) Therapiestudien zur adjuvanten und palliativen Therapie. ONKOLOGE, 1: 57-60 IF: 0,173 anteiliger IF: 0,0865

110. Köhne CH, Schmoll HJ, Wilke H, Käufer C, Rauschecker H, Andreesen R, Ohl U, Lange HJ, Klaasen U, Westerhausen M, Hiddemann W, Schott G, Bade J, Strohmeyer G, Schöffski P, Schubert U, Hecker H: (1995) Interferonalpha does not improve the antineoplastic efficacy of high-dose infusional 5- fluorouracil plus folinic acid in advanced colorectal cancer: First results of a randomized multicenter study by the Association of Medical Oncology of the German Cancer Society (AIO). ANN ONCOL, 6: 461-466 IF: 2,256, anteiliger IF: 0,05014 111. Kuczyk MA, Bokemeyer C, Fichna B, Truss M, Schmoll HJ, Jonas U: (1995) [Differentiated teratoma as late recurrence of metastatic nonseminomatous testicular germ cell tumor. Case report and clinical problems]. Urologe A, 34: 480-4. 8848861 IF: 0,381, anteiliger IF: 0,03176 112. Kuczyk MA, Bokemeyer C, Schmoll HJ, Jonas U: (1995) The prognostic role of alterations of the p53 tumor suppressor gene in superficial and advanced stage bladder cancer. Onkologie, 18: 202-210 IF: 0,462, anteiliger IF: 0,07702 113. Rhomberg W, Schmoll HJ, Schneider B: (1995) High frequency of metalworkers among patients with seminomatous tumors of the testis: a casecontrol study. AM J IND MED, 28: 79-87. 7573077 IF: 0,987, anteiliger IF: 0,32907 114. Thiel I, Schmoll HJ, Bokemeyer C: (1995) Primary osteogenic sarcoma of the breast: Report of a case and a short review of the literature. Onkologie, 18: 357-361 IF: 0,462, anteiliger IF: 0,15403 115. Bokemeyer C 1, Kuczyk M, Fichna B, Jonas U, Poliwoda H, Schmoll H. Late relapse of testicular cancer presenting as differentiated teratoma - report of a case and discussion of the clinical implications. Oncol Rep. 1995 Jul;2(4):615-8. IF:0,407 anteiliger IF:0,13567 1995 Summe Bewertung = 10,76778 Summe IF = 42,673 116. Andrews PW, Casper J, Damjanov I, Duggan-Keen M, Giwercman A, Hata JI, von Keitz A, Looijenga LHJ, Millan JL, Oosterhuis JW, Pera M, Sawada M, Schmoll HJ, Skakkebaek NE, van Putten W, Stern P: (1996) Comparative analysis of cell surface antigens expressed by cell lines derived from human germ cell tumors. Int J Cancer, 66: 806-816 IF: 3,534, anteiliger IF: 0,08416

117. Berger C, Bokemeyer C, Schuppert F, Schmoll HJ: (1996) Endocrinological late effects after chemotherapy for testicular cancer. BRIT J CANCER, 73: 1108-1114 IF: 3,666, anteiliger IF: 1,22188 118. Beyer J, Bokemeyer C, Schmoll HJ, Siegert W: (1996) Hochdosischemotherapie bei Hodentumoren. ONKOLOGE, 2: 28-32 IF: 0,173 anteiliger IF: 0,02884 119. Beyer J, Kramar A, Mandanas R, Linkesch W, Greinix A, Droz JP, Diehl A, Bokemeyer C, Schmoll HJ, Nichols CR, Einhorn LH, Siegert W: (1996) High-dose chemotherapy as salvage treatment in germ cell tumors: a multivariate analysis of prognostic variables. J CLIN ONCOL, 14: 2638-2645 IF: 7,881, anteiliger IF: 0,26275 120. Beyer J, Kramer A, Mandanas R, Linkesch W, Greinix A, Droz JP, Culine S, Diehl A, Bokemeyer C, Schmoll HJ, Einhorn LH, Nichols CR, Siegert W: (1996) Treatment outcome of high-dose chemotherapy as salvage treatment in male germ cell tumors: a multivariate analysis of prognostic factors. J CLIN ONCOL, 14: 2638-2645 IF: 7,881, anteiliger IF: 0,23887 121. Bokemeyer C, Beyer J, Metzner B, Rüther U, Weißbach L, Köhrmann U, Verbeek W, Harstrick A, Schmoll HJ: (1996) Phase II study of paclitaxel in patients with relapsed or cisplatin-refractory cancer. ANN ONCOL, 7: 31-34 IF: 2,736, anteiliger IF: 0,91191 122. Bokemeyer C, Fels LM, Dunn TA, Voigt W, Gaedeke J, Schmoll HJ, Stolte H: (1996) Silibinin protects against cisplatin-induced nephrotoxicity without compromising cisplatin or ifosfamide antitumor activity. BRIT J CANCER, 74: 2036-2041 IF: 3,666, anteiliger IF: 0,24445 123. Bokemeyer C, Köhrmann O, Tischler J, Weißbach L, Räth U, Haupt A, Schöffski P, Schmoll HJ: (1996) A randomized trial of cisplatin, etoposide and bleomycin (PEB) versus carboplatin, etoposide and bleomycin (CEB) for patients with good risk metastatic non-seminomatous germ cell tumors. ANN ONCOL, 7: 1015-1022 IF: 2,736, anteiliger IF: 0,91191 124. Bokemeyer C, Kuczyk MA, Dunn TA, Serth T, Hartmann K, Jonasson J, Jonas U, Schmoll HJ: (1996) Expression of stem cell factor and its receptor c- kit protein in normal testicular tissue and malignant germ-cell tumors. J CANCER RES CLIN, 122: 301-306 IF: 1,093, anteiliger IF: 0,3643 125. Bokemeyer C, Kuczyk MA, Köhne CH, Einsele H, Kynast B, Schmoll HJ: (1996) Hematopoetic growths factors and treatment of testicular cancer: Biological interactions routine use and dose-intensive chemotherapy. ANN HEMATOL, 72: 1-9 IF: 1,206, anteiliger IF: 0,40196

126. Bokemeyer C, Kuczyk MA, Köhne H, Einsele H, Kynast B, Schmoll HJ: (1996) Treatment of testicular cancer and hematopoietic growth factors: Biological interactions routine use and dose-intensive chemotherapy. ANN HEMATOL, 7: 1-9 IF: 1,206, anteiliger IF: 0,40196 127. Bokemeyer C, Kuczyk MA, Köhne H, Haupt A, Schmoll HJ: (1996) Das Risiko sekundärer Neoplasien nach Behandlung maligner Keimzelltumoren des Hodens. Med Klin Intensivmed Notfmed, 91: 703-710 IF: 0,468 anteiliger IF: 0,156 128. Bokemeyer C, Kuczyk MA, Serth, Hartmann JT, Schmoll HJ, Jonas U, Kanz L: (1996) Treatment of clinical stage I testicular cancer and a possible role for new biological prognostic parameters. J CANCER RES CLIN, 122: 575-584 IF: 1,093, anteiliger IF: 0,07288 129. Bokemyer C, Berger C, Kuczyk MA, Schmoll HJ: (1996) Evaluation of long-term toxicity after chemotherapy for testicular cancer. J CLIN ONCOL, 14: 2923-2932 IF: 7,881, anteiliger IF: 2,62674 130. Borchard E, Engelhardt, Frommhold, Hartung, Hermanek, Herrmann, Hossfeld, Junginger, Kirchner, Kreuser, Meyer, Müller, Pichlmaier, Queißer, Schlag, Schmoll, Stock, Wilke: (1996) Konsens der CAO, AOI und ARO zur Diagnostik und Therapie des primären Magenlymphoms. Onkologie, 19: 360-363 IF: 0,451, anteiliger IF: 0,0094 131. Dunn TA, Schmoll HJ, Grünwald V, Bokemeyer C, Casper J: (1996) Amifostine does not alter the antitumor activity of cisplatin in a pre-clinical model of testicular cancer. ANTI-CANCER DRUG, 7: 1-5 IF: 1,397, anteiliger IF: 0,15525 132. Erlichman C, Fine S, Kerr I, Hoffmann W, Görg C, Schmoll HJ, Preusser P, Thuerlimann B, Gustavsson B: (1996) A phase II trial of 5- fluorouracil and 1-leucovorin in patients with metastatic colorectal cancer. AM J CLIN ONCOL-CANC, 19: 26-31 IF: 0,921, anteiliger IF: 0,04387 133. Fels LM, Bokemeyer C, van Rhee J, Schmoll HJ, Stolte H: (1996) Evaluation of late nephrotoxicity in long-term survivors of Hodgkin's disease. ONCOLOGY-BASEL, 53: 73-78 IF: 2,097, anteiliger IF: 0,23305 134. Hartmann JT, Thiel I, Schmoll HJ, Einsele H, Kanz L, Bokemeyer C: (1996) Malignant fibrous histiocytoma of bone - review of thirteen cases. Oncol Rep, 3: 1-5 IF: 0,476, anteiliger IF: 0,03967 135. Rambusch EG, Schuppert F, Müller-Kunert E, Stöcker W, Bokemeyer C, Schmoll HJ, von zur Mühlen A: (1996) Zytokintherapie und Endokrinium: Ist es sinnvoll, mehr als die Schilddrüse zu untersuchen? Med Klin

Intensivmed Notfmed, 91: 59-65 IF: 0,468 anteiliger IF: 0,0312 136. Rüther U, Nunnensiek C, Sessler R, Stilz S, Ulshöfer T, Müller HAG, Bader H, Bokemeyer C, Schmoll HJ, Toomes H, Jipp P: (1996) Efficacy of antiestrogen treatment in a benign metastasizing leimyoma with paraneoplastic estradiol production. Oncol Rep, 3: 293-299 IF: 0,476, anteiliger IF: 0,01763 137. Schmoll HJ: (1996) Die Therapie von Keimzelltumoren: Modell für eine interdisziplinäre Behandlungsstrategie. Med Klin Intensivmed Notfmed, 3: 80-84 IF: 1,709 anteiliger IF: 1,709 138. Schmoll HJ: (1996) Development of Treatment for Advanced Colorectal Cancer: Infusional 5-FU and the role of new agents. EUR J CANCER, 32: S18-22 IF: 2,017, anteiliger IF: 2,017 139. Schmoll HJ, Bokemeyer C: (1996) Sequential intermediate high-dose chemotherapy in the primary treatment of poor risk testicular cancer. BONE MARROW TRANSPL, 18: 48-49 IF: 2,771, anteiliger IF: 1,3855 140. Hartmann J 1, Thiel I, Schmoll H, Einsele H, Kanz L, Bokemeyer C. Malignant fibrous histiocytoma of bone - Review of thirteen cases. Oncol Rep. 1996 Sep;3(5):813-7. IF: 0,407 anteiliger IF: 0,03392 1996 Summe Bewertung = 14,02106 Summe IF = 50,527 141. Bamberg M, Schmoll HJ, Weißbach L, Beyer J, Bokemeyer C, Harstrick A, Höltl W, Souchon R, Vogler H: (1997) An interdiciplinary consensus conference on the diagnosis and therapy of testicular tumors. Strahlenther Onkol, 173: 397-406 IF: 2,5 anteiliger IF: 0,14286 142. Berkovic D, Grundel O, Berkovic K, Wildfang I, Hess CF, Schmoll HJ: (1997) Synergistic cytotoxic effects of either phospholipid analogues and ionizing radiation in human carcinoma cells. Radiother Oncol, 43: 293-301 IF: 1,924, anteiliger IF: 0,64127

143. Bokemeyer C, Franzke A, Hartmann JT, Schöber C, Arseniev L, Metzner B, Link H, Kanz L, Schmoll HJ: (1997) A Phase I/ II Study of Sequential, Dose-Escalated, High-Dose Ifosfamide plus Doxorubicin with Peripheral Blood Stem Cell Support for the Treatment of Patients with Advanced Soft Tissue Sarcomas. CANCER-AM CANCER SOC, 6: 1221-1227 IF: 3,296, anteiliger IF: 1,09856 144. Bokemeyer C, Nowak P, Haupt A, Metzner B, Köhne H, Hartmann JT, Kanz L, Schmoll HJ: (1997) Treatment of brain metastases in patients with testicular cancer. J CLIN ONCOL, 15: 1449-1454 IF: 7,878, anteiliger IF: 2,62574 145. Dunn TA, Schmoll HJ, Grünewald V, Bokemeyer C, Casper J: (1997) Comparative cytotoxicity of oxaliplatin and cisplatin in non-seminomatous germ cell cancer cell lines. INVEST NEW DRUG, 15: 109-114 IF: 0,543, anteiliger IF: 0,06035 146. Dunn T, Schmoll HJ, Grünewald V, Casper J, Bokemeyer C: (1997) Pre-clinical activity of taxol in nonseminomatous germ cell tumor cell lines and nude mouse xenografts. INVEST NEW DRUG, 15: 91-98 IF: 0,543, anteiliger IF: 0,06035 147. Harstrick A, Köhne CH, Hiddemann W, Preusser P, Berns T, Seeber S, Wilke H, Schmoll HJ: (1997) Modulation of 5-Flourouracil with Metotrexate and Low-dose N-(phosphonacety)-L-aspartete (PALA) in inactive advanced pancreatic carcinoma. ANN ONCOL, 8: 917-918 IF: 2,548, anteiliger IF: 0,84925 148. Hartmann JT, Candelaria M, Kuczyk MA, Schmoll HJ, Bokemeyer C: (1997) Comparison of histological results from the resection of residual masses at different sites after chemotherapy for metastatic nonseminomatous germ cell tumors. EUR J CANCER, 33: 843-847 IF: 2,407, anteiliger IF: 0,2675 149. Hartmann JT, Schmoll HJ, Kuczyk MA, Candelaria M, Bokemeyer C: (1997) Postchemotherapy resections of residual masses from metastatic nonseminomatous testicular germ cell tumors. ANN ONCOL, 8: 531-538 IF: 2,548, anteiliger IF: 0,28317 150. Hartmannn JT, Schmoll HJ, Thiel I, Kanz L, Bokemeyer C: (1997) Klinische Verlaufsbeobachtung von Patienten mit malignem fibrösen Histiozytom des Knochens und Übersicht zur chemotherapeutischen Behandlung. TUMORDIAGN THER, 1: Jan 34 IF: 0,148, anteiliger IF: 0,01645 151. Hartmann, Schmoll E, Bokemeyer C, Fety, Lucas, D Agay, Schmoll HJ: (1997) Hepatic arterial infusion of the nitrosourea derivate fotemustine for the treatment of liver metastases from colorectal carcinoma. Oncol Rep, 4: 167-172 IF: 0,407, anteiliger IF: 0,13565 152. Köhne C, Harstrick A, Hiddemann W, Schöffski P, Wilke H, Bokemeyer C, Dörken B, Schmoll HJ: (1997) Modulation of 5-Flourouracil with

Metotrexate and Low-dose N-(phosphonacety)-L-aspartete in Patients with Advanced Colorectal Cancer. Results of a Phase II Study. EUR J CANCER, 33: 1896-1899 IF: 2,407, anteiliger IF: 0,80225 153. Köhne C, Wilke H, Hiddemann W, Bokemeyer C, Lohrmann HP, Bodenstein H, Preiss J, Rauschecker H, Hill H, Käufer C, Fischer JT, Ohl U, Urbanitz D, Balleisen L, Schmoll HJ: (1997) Phase II Evaluation of 5- Flourouracil plus Folinic acid and alpha 2b-interferon in metastatic colorectal cancer. ONCOLOGY-BASEL, 54: 98-101 IF: 2,141, anteiliger IF: 0,7136 154. Malek NP, Casper J, Looijenga LH, Strohmeyer T, Schmoll HJ, Nordheim A, Janknecht R: (1997) Quantification of additional short arms of chromosome 12 in germ cell tumors using the polymerase chain reaction. EUR J CANCER, 33: 1488-1494 IF: 2,407, anteiliger IF: 0,1605 155. Schmoll HJ: (1997) Prognostic factors for advanced seminoma - a solid basis for clinical trials (Editorial). EUR J CANCER, 9: 1347-1350 IF: 2,407, anteiliger IF: 2,407 156. Schmoll HJ, Bamberg M, Weißbach L: (1997) Interdisziplinäre Konsensus-Konferenz zur Diagnostik und Therapie von Hodentumoren. Onkologie, 20: 164-170 IF: 0,328, anteiliger IF: 0,10932 157. Schmoll HJ, Büchele T, Schöber C: (1997) The role of second line chemotherapy in colorectal cancer. Onkologie, 20: 288-294 IF: 0,328, anteiliger IF: 0,10932 158. Schöber C, Galanski M, Jörgensen M, Schmoll HJ: (1997) Management of endocrine pancreatic tumors. WIEN KLIN WOCHENSCHR, 147: 18-23 IF: 0,411, anteiliger IF: 0,13699 159. Seliger B, Dunn T, Schwenzer A, Casper J, Huber C, Schmoll HJ: (1997) Analysis of the MHC-Class I antigen presentation machinery in a human embryonal carcinoma cell line: evidence for suppression of TAP, LMP and MHC class I expression. SCAND J IMMUNOL, 46: 625-632 IF: 1,749, anteiliger IF: 0,58294 160. Weißbach L, Bamberg M, Schmoll HJ: (1997) Interdisciplinary consensus conference on diagnosis and therapy of testicular cancer. Urologe A, 36: 362-368 IF: 0,513, anteiliger IF: 0,17098 161. Hartmann J 1, Schmoll E, Bokemeyer C, Fety R, Lucas C, Dagay L, Schmoll H Hepatic arterial infusion of the nitrosourea derivate fotemustine for the treatment of liver metastases from colorectal carcinoma. Oncol Rep. 1997 Jan-Feb;4(1):167-72.

IF: 0,407 anteiliger IF: 0,1357 1997 Summe Bewertung = 11,36687 Summe IF = 35,34 162. Beyer J, Bokemeyer C, Schmoll HJ, Siegert W: (1998) Salvagetherapie rezidivierter und refraktärer Hodentumoren. ONKOLOGE, 4: 541-546 IF: 0,1 anteiliger IF: 0,017 163. Beyer J, Schmoll HJ: (1998) Prognosefaktoren bei metastasierten seminomatösen und nichtseminomatösen Hodentumoren. ONKOLOGE, 4: 518-523 IF: 0,1 anteiliger IF: 0,05 164. Bokemeyer C, Berger CC, Hartmann JT, Kollmannsberger C, Schmoll HJ, Kuczyk MA, Kanz L: (1998) Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer. BRIT J CANCER, 77: 1355-1362 IF: 3,036, anteiliger IF: 0,20244 165. Bokemeyer C, Gerl A, Harstrick A, Schmoll HJ: (1998) Therapie des fortgeschrittenen nichtseminomatösen Keimzelltumors. ONKOLOGE, 4: 532-540 IF: 0,1 anteiliger IF: 0,0333 166. Bokemeyer T, Harstrick A, Beyer J, Metzner B, Rüther U, Hartmann JT, Holstein K, Derigs HG, de Wit R, Casper J, Schöffski P, Kuhrer I, Illiger HJ, Kempf B, Reichle A, Foller A, Hossfeld DK, Fischer JT, Berdel WE, Gerhartz HH, Kirchner H, Pflüger KH, Ostermann H, Kanz L, Schmoll HJ: (1998) The use of dose-intensified chemotherapy in the treatment of metastatic nonseminomatous testicular germ cell tumors. German Testicular Cancer Study Group. SEMIN ONCOL, 25: 24-32 IF: 2,252, anteiliger IF: 0,75059 167. Dunn T, Schmoll HJ, Rie C, Hartmann K, Casper J: (1998) Production and pre-clinical significance of hematopoietic peptide growth factor (HPGF) in human non-seminomatous germ cell tumor (NSGCT) cell lines. J CANCER RES CLIN, 124: 435-443 IF: 1,183, anteiliger IF: 0,13147 168. Hartmann JT, Köhne CH, Schmoll HJ, Daikeler T, Kanz L, Bokemeyer C: (1998) Is continuous 24-hour infusion of 5-Flourouracil plus high-dose folinic acid effective in patients with progressive or recurrent colorectal cancer? A phase II Study. ONCOLOGY-BASEL, 55: 320-325 IF: 2,858, anteiliger IF: 0,23821 169. Hartmann JT, Schmoll E, Bokemeyer C, Fety R, Lucas C, Giroux B, Schmoll HJ: (1998) Phase I Pharmacological Study of Intra-arterially Infused

Fotemustine for Colorectal Liver Metastases. EUR J CANCER, 34: 87-91 IF: 2,743, anteiliger IF: 0,91424 170. Köhne CH, Schöffski P, Wilke H, Kaufer C, Andreesen R, Ohl U, Klaasen U, Westerhausen M, Hiddemann W, Schott G, Harstrick A, Bade J, Horster A, Schubert U, Hecker H, Dörken B, Schmoll HJ: (1998) Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: results of a randomized trial in patients with advanced colorectal cancer. J CLIN ONCOL, 16: 418-426 IF: 8,228, anteiliger IF: 2,74239 171. Kollmannsberger C, Beyer J, Droz JP, Harstrick A, Hartmann JT, Biron P, Flechon A, Schöffski P, Kuczyk M, Schmoll HJ, Kanz L, Bokemeyer C: (1998) Secondary leukemia following high cumulative doses for Etoposide in Patients treated for advanced germ cell tumors. J CLIN ONCOL, 16: 3386-3391 IF: 8,228, anteiliger IF: 0,27432 172. Korfel A, Scheulen ME, Schmoll HJ, Gründel O, Harstrick A, Knoche M, Fels LM, Skorzec M, Bach F, Baumgart J, Saß G, Seeber S, Thiel E, Berdel WE: (1998) Phase I Clinical and Pharmacokinetic Study of Titanocene Dichloride in adults with advanced solid tumors. CLIN CANCER RES, 4: 2701-2708 IF: 2,941, anteiliger IF: 0,08171 173. Schmoll HJ: (1998) Is there a standard adjuvant treatment for colon cancer? (Editorial). EUR J CANCER, 34: 1659-1663 IF: 2,743, anteiliger IF: 2,743 174. Schmoll HJ: (1998) Is there a standard adjuvant treatment for rectal cancer? (Editorial). EUR J CANCER, 34: 1827-1835 IF: 2,743, anteiliger IF: 2,743 175. Schmoll HJ, Beyer J: (1998) Prognostic factors in metastatic germ cell tumors. SEMIN ONCOL, 25: 174-186 IF: 2,252, anteiliger IF: 1,126 176. Schmoll HJ, Weißbach L, Bamberg M: (1998) Editorial: Therapie des Hodentumors: das Zauberwort heißt Interdisziplinarität. ONKOLOGE, 4: 471-472 IF: 0,1 anteiliger IF: 0,0333 1998 Summe Bewertung = 11,94738 Summe IF = 39,207 177. Bokemeyer C, Gerl A, Schöffski P, Harstrick A, Niederle N, Beyer J, Casper J, Schmoll HJ: (1999) Gemcitabine in patients with relapsed or Cisplatin-refractory testicular cancer. J CLIN ONCOL, 17: 512-516 IF: 7,963, anteiliger IF: 2,65407

178. Bokemeyer C, Kollmannsberger C, Harstrick A, Beyer J, Gerl A, Casper J, Metzner B, Hartmann JT, Schmoll HJ, Kanz L: (1999) Treatment of patients with Cisplatin-refractory testicular germ-cell cancer. Int J Cancer, 83: 848-851 IF: 3,545, anteiliger IF: 0,14774 179. Bokemeyer C, Kollmannsberger C, Meisner C, Harstrick A, Beyer J, Metzner B, Hartmann JT, Schmoll HJ, Einhorn L, Kanz L, Nichols C: (1999) First-Line High-Dose Chemotherapy compared with standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumors: A multivariate and matched-pair analysis. J CLIN ONCOL, 17: 3450-3456 IF: 7,963, anteiliger IF: 0,29498 180. Dempke W, Behrmann C, Schöber C, Büchele T, Grothey A, Schmoll HJ: (1999) Diagnostisches und therapeutisches Management der oberen Einflussstauung. Med Klin Intensivmed Notfmed, 94: 681-684 IF: 0,5 anteiliger IF: 0,1666 181. Dempke W, Büchele T, Wolf HH, Grothey A, Schmoll HJ: (1999) Diagnostik und Therapie maligner Pleura- und Perikardergüsse. Onkologie, 22: 526-529 IF: 0,382, anteiliger IF: 0,12732 182. Dempke W, Voigt W, Grothey A, Schmoll HJ: (1999) Preferential repair of the N-ras gene in K562 cells after exposure to cisplatin. ANTI-CANCER DRUG, 10: 545-549 IF: 1,594, anteiliger IF: 0,53128 183. Fossa SD, Bokemeyer C, Gerl A, Culine S, Jones WG, Mrad GM, Germa-Luch JR, Pont J, Schmoll HJ, Tjulandin S: (1999) Treatment outcome of patients with brain metastases from malignant germ cell tumors. CANCER- AM CANCER SOC, 85: 988-997 IF: 3,632, anteiliger IF: 0,15136 184. Grothey A, Voigt W, Schöber C, Müller T, Dempke W, Schmoll HJ: (1999) The role of insulin-like growth factor I and its receptor in cell growth, transformation, apoptosis, and chemoresistance in solid tumors. J CANCER RES CLIN, 125: 166-173 IF: 1,052, anteiliger IF: 0,35063 185. Hartmann JT, Albrecht C, Schmoll HJ, Kuczyk MA, Kollmannsberger C, Bokemeyer C: (1999) Long-term effects on sexual function and fertility after treatment of testicular cancer. BRIT J CANCER, 80: 801-807 IF: 3,282, anteiliger IF: 0,27355 186. Kellner O, Dempke W, Schmoll HJ: (1999) Glukose-Infusionen - eine mögliche effektive Therapieoption bei der Ifosfamid-induzierten Enzephalopathie. Dtsch Med Wochenschr, 124: 1086-1087 IF: 0,684, anteiliger IF: 0,22798 187. Schmoll HJ: (1999) Treatment of testicular tumours based on risk factors. CURR OPIN UROL, 9: 431-438 IF: 2,59 anteiliger IF: 2,59

188. Schmoll HJ: (1999) Standards in der Behandlung kolorektaler Karzinome - Wunsch und Wirklichkeit. ONCOLOGY-BASEL, 99: 6-7 IF: 2,684, anteiliger IF: 2,684 189. Schmoll HJ, Büchele T, Grothey A, Dempke W: (1999) Where do we stand with 5-FU? SEMIN ONCOL, 26: 589-605 IF: 2,986, anteiliger IF: 0,99523 1999 Summe Bewertung = 8,43815 Summe IF = 35,767 190. Brieger P, Wolf HH, Schmoll HJ, Marneros A: (2000) Manic episode in an ifosfamide-treated patient. GEN HOSP PSYCHIAT, 22: 52-53 IF: 1,512, anteiliger IF: 0,25205 191. Büchele T, Grothey A, Schmoll HJ: (2000) Neue Perspektiven mit neuen Zytostatika in der Behandlung des kolorektalen Karzinoms. ONKOLOGE, 6: 410-419 IF: 0,12 anteiliger IF: 0,04 192. Dempke W, Voigt W, Grothey A, Hill BT, Schmoll HJ: (2000) Cisplatin resistance and oncogenes - a review. ANTI-CANCER DRUG, 11: 225-236 IF: 1,57, anteiliger IF: 0,52328 193. Dempke W, von Poblozki A, Grothey A, Schmoll HJ: (2000) Human hematopoietic growth factors: old lessons and new perspectives. ANTICANCER RES, 20: 5155-5164 IF: 1,331, anteiliger IF: 0,44362 194. Grothey A, Kegel T, Dempke W, Schmoll HJ: (2000) Systemische Therapie des hepatozellulären Karzinoms. ONKOLOGE, 6: 327-335 IF: 1,41 anteiliger IF: 0,47 195. Kellner O, Voigt W, Schneyer U, Dempke W, Schmoll HJ: (2000) HCGinduced hyperthyreosis in germ cell cancer. ANTICANCER RES, 20: 5135-8 IF: 1,331, anteiliger IF: 0,44362 196. Kollmannsberger C, Nichols C, Bamberg M, Hartmann JT, Schleucher N, Beyer J, Schöffski P, Gerigs G, Rüther U, Bohlke I, Schmoll HJ, Kanz L, Bokemeyer C: (2000) First-Line High-Dose chemotherapy + radiation therapy in patients with metastatic germ-cell cancer and brain metastases. ANN ONCOL, 11: 553-559 IF: 3,249, anteiliger IF: 0,09847 197. Schmiegel W, Adler G, Frühmorgen P, Fölsch U, Greaven U, Layer P, Petrasch S, Porschen R, Pox C, Sauerbruch T, Schmoll HJ, Zeitz M: (2000) Kolorektales Karzinom: Prävention und Früherkennung in der asymptomatischen Bevölkerung - Vorsorge bei Risikopatienten - Endoskopische Diagnostik, Therapie und Nachsorge von Polypen und Karzinomen. Z Gastroenterol, 38: 49-75